Suppr超能文献

产超广谱β-内酰胺酶(ESBL)的肠杆菌科细菌:诊断、预防及药物治疗的相关考量

Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.

作者信息

Rupp Mark E, Fey Paul D

机构信息

Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA.

出版信息

Drugs. 2003;63(4):353-65. doi: 10.2165/00003495-200363040-00002.

Abstract

Extended spectrum beta-lactamase (ESBL)-producing organisms pose unique challenges to clinical microbiologists, clinicians, infection control professionals and antibacterial-discovery scientists. ESBLs are enzymes capable of hydrolysing penicillins, broad-spectrum cephalosporins and monobactams, and are generally derived from TEM and SHV-type enzymes. ESBLs are often located on plasmids that are transferable from strain to strain and between bacterial species. Although the prevalence of ESBLs is not known, it is clearly increasing, and in many parts of the world 10-40% of strains of Escherichia coli and Klebsiella pneumoniae express ESBLs. ESBL-producing Enterobacteriaceae have been responsible for numerous outbreaks of infection throughout the world and pose challenging infection control issues. Clinical outcomes data indicate that ESBLs are clinically significant and, when detected, indicate the need for the use of appropriate antibacterial agents. Unfortunately, the laboratory detection of ESBLs can be complex and, at times, misleading. Antibacterial choice is often complicated by multi-resistance. Many ESBL-producing organisms also express AmpC beta-lactamases and may be co-transferred with plasmids mediating aminoglycoside resistance. In addition, there is an increasing association between ESBL production and fluoroquinolone resistance. Although in in vitro tests ESBLs are inhibited by beta-lactamase inhibitors such as clavulanic acid, the activity of beta-lactam/beta-lactamase inhibitor combination agents is influenced by the bacterial inoculum, dose administration regimen and specific type of ESBL present. Currently, carbapenems are regarded as the drugs of choice for treatment of infections caused by ESBL-producing organisms. Unfortunately, use of carbapenems has been associated with the emergence of carbapenem-resistant bacterial species such as Stenotrophomonas sp. or Pseudomonas sp.

摘要

产超广谱β-内酰胺酶(ESBL)的微生物给临床微生物学家、临床医生、感染控制专业人员和抗菌药物研发科学家带来了独特的挑战。ESBL是一类能够水解青霉素、广谱头孢菌素和单环β-内酰胺类药物的酶,通常由TEM型和SHV型酶衍生而来。ESBL通常位于可在菌株间以及不同细菌种属间转移的质粒上。虽然ESBL的流行情况尚不清楚,但显然在不断增加,在世界许多地区,10%至40%的大肠杆菌和肺炎克雷伯菌菌株可产生ESBL。产ESBL的肠杆菌科细菌已在全球引发了众多感染暴发,并带来了具有挑战性的感染控制问题。临床结果数据表明,ESBL具有临床意义,一旦检测到,就表明需要使用合适的抗菌药物。不幸的是,ESBL的实验室检测可能很复杂,有时还会产生误导。抗菌药物的选择常常因多重耐药性而变得复杂。许多产ESBL的微生物还可表达AmpCβ-内酰胺酶,并且可能与介导氨基糖苷类耐药性的质粒共同转移。此外,ESBL产生与氟喹诺酮耐药性之间的关联也在增加。虽然在体外试验中,ESBL可被克拉维酸等β-内酰胺酶抑制剂抑制,但β-内酰胺/β-内酰胺酶抑制剂复方制剂的活性会受到细菌接种量、给药方案和所存在的ESBL具体类型的影响。目前,碳青霉烯类药物被视为治疗产ESBL微生物所致感染的首选药物。不幸的是,碳青霉烯类药物的使用与嗜麦芽窄食单胞菌或铜绿假单胞菌等耐碳青霉烯类细菌物种的出现有关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验